The Experts below are selected from a list of 3978 Experts worldwide ranked by ideXlab platform
David L. Vesely - One of the best experts on this subject based on the ideXlab platform.
-
Insulin
2014Co-Authors: Ying Sun, Ehrentraud J. Eichelbaum, Hai Wang, David L. VeselyAbstract:AIM: This study is to determine if four endogenous growth inhibitors (i.e. four car-diac hormones) can inhibit the activity of extracellular-signal regulated kinases 1/2 (ERK 1/2) stimulated by endogenous growth promoters i.e. insulin and epidermal growth factor (EGF). METHODS: The phosphorylation of ERK 1/2 was measured with Western blots, while DNA synthesis was measured by bromodeoxyuridine incorporation. RESULTS: These four peptide hormones, i.e. Vessel Dilator, kaliuretic peptide, long acting natriuretic peptide, and atrial natriuretic peptide decreased insulin’s (10 µM) 66 % enhanced phosphorylation in human prostate adenocarcinoma cells to 10%, 8%, 24%, and 13 % above non-stimulated ERK 1/2 activity, respectively. The EGF’s (50 ng/ml) 66 % enhanced phosphorylation of ERK 1/2 in human prostate cancer cells was inhibited to-11 % (i.e. 117 % decrease), 4%, 13 % and 16 % by Vessel Dilator, atrial natri-uretic peptide, long acting natriuretic peptide, and kaliuretic peptide compared to non-stimulated ERK 1/2 activity, respectively. In human pancreatic cancer cells insulin and epidermal growth factor stimulated ERK 1/2 to a larger extent, i.e., 98 % and 472%
-
Subcutaneous pharmacokinetics of the cardiac hormone Vessel Dilator.
Clinical and experimental pharmacology & physiology, 2014Co-Authors: Qingyu Zhou, Glenn Whelan, Shu-feng Zhou, Meghan L. Lane, David L. VeselyAbstract:Summary Vessel Dilator, a hormone synthesized in the heart, eliminates 71% of human small-cell lung cancers and 67% of human breast cancers growing in mice when given subcutaneously (s.c.) via osmotic pumps. The pharmacokinetics of s.c. administered Vessel Dilator have not been evaluated previously. In the present study, the pharmacokinetics of Vessel Dilator following s.c. bolus (ScB) or 3 h s.c. infusion (ScI) were compared with those following i.v. bolus (IvB) administration in male Fischer 344 rats. The half-life (t½) of Vessel Dilator after ScI, IvB and ScB was 54, 43 and 30 min, respectively. The tmax for Vessel Dilator after IvB, ScB and ScI administration was 1.5, 23 and 156 min, respectively, whereas the corresponding Cmax values were 3749, 887 and 471 ng/L (normalized against the dose used for ScB and IvB). The area under the curve (AUC0–∞) for Vessel Dilator was 1166, 880 and 1652 ng h/mL (normalized) following IvB, ScB and ScI administration, respectively. The volume of distribution for Vessel Dilator was 2.38, 0.92 and 1.08 L following IvB, ScB and SCI administration, respectively; corresponding clearance values were 1.69, 1.50 and 0.78 L/h, respectively. Plasma concentrations of Vessel Dilator after each of the three methods of administration mirrored their predicted concentration–time profiles. We conclude that Vessel Dilator administered via ScI has a significantly greater AUC and t½ and slowed clearance compared with IvB or ScB administration (P
-
subcutaneous pharmacokinetics of the cardiac hormone Vessel Dilator
Clinical and Experimental Pharmacology and Physiology, 2014Co-Authors: Qingyu Zhou, Glenn Whelan, Shu-feng Zhou, Meghan L. Lane, David L. VeselyAbstract:Summary Vessel Dilator, a hormone synthesized in the heart, eliminates 71% of human small-cell lung cancers and 67% of human breast cancers growing in mice when given subcutaneously (s.c.) via osmotic pumps. The pharmacokinetics of s.c. administered Vessel Dilator have not been evaluated previously. In the present study, the pharmacokinetics of Vessel Dilator following s.c. bolus (ScB) or 3 h s.c. infusion (ScI) were compared with those following i.v. bolus (IvB) administration in male Fischer 344 rats. The half-life (t½) of Vessel Dilator after ScI, IvB and ScB was 54, 43 and 30 min, respectively. The tmax for Vessel Dilator after IvB, ScB and ScI administration was 1.5, 23 and 156 min, respectively, whereas the corresponding Cmax values were 3749, 887 and 471 ng/L (normalized against the dose used for ScB and IvB). The area under the curve (AUC0–∞) for Vessel Dilator was 1166, 880 and 1652 ng h/mL (normalized) following IvB, ScB and ScI administration, respectively. The volume of distribution for Vessel Dilator was 2.38, 0.92 and 1.08 L following IvB, ScB and SCI administration, respectively; corresponding clearance values were 1.69, 1.50 and 0.78 L/h, respectively. Plasma concentrations of Vessel Dilator after each of the three methods of administration mirrored their predicted concentration–time profiles. We conclude that Vessel Dilator administered via ScI has a significantly greater AUC and t½ and slowed clearance compared with IvB or ScB administration (P < 0.001), suggesting that s.c. infusion is the preferred method of administration, based on pharmacokinetics, to treat cancers.
-
Cardiac hormones target nuclear oncogenes c-Fos and c-Jun in carcinoma cells.
European journal of clinical investigation, 2013Co-Authors: Neil J. Manimala, Meghan L. Lane, Chelsea Frost, Mariana Higuera, Rana Beg, David L. VeselyAbstract:Background c-Fos is a cellular proto-oncogene which dimerizes with c-Jun proto-oncogene to form AP-1 transcription factor, which upregulates transcription of genes involved in proliferation and cancer formation. Four cardiac hormones, that is, long-acting natriuretic peptide (LANP), Vessel Dilator, kaliuretic peptide (KP) and atrial natriuretic peptide (ANP) with anticancer effects in vivo are potent inhibitors of the Ras-MEK 1/2-ERK 1/2 kinase cascade and signal transducer and activator of transcription-3 (STAT-3) that activate c-Fos and c-Jun. These four cardiac hormones were investigated for their effects on proto-oncogenes c-Fos and c-Jun within the nucleus of cancer cells. Materials and methods Four cardiac hormones were evaluated for their ability to decrease proto-oncogenes c-Fos and c-Jun, measured by ELISA in extracted nuclei of three human cancer cell lines. Results Vessel Dilator, LANP, KP and ANP over a concentration range of 100 pM–10 μM, maximally decreased c-Fos by 61%, 60%, 61% and 59% in human hepatocellular cancer cells, by 82%, 74%, 78% and 74% in small-cell lung cancer cells, and by 82%, 73%, 78% and 74% in human renal adenocarcinoma cells. c-Jun was maximally reduced by Vessel Dilator, LANP, KP and ANP by 43%, 31%, 61% and 35% in hepatocellular cancer cells, by 65%, 49%, 59% and 40% in small-cell lung cancer cells, and by 47%, 43%, 57% and 49% in renal cancer cells. Conclusion Four cardiac hormones are potent inhibitors of c-Fos and c-Jun proto-oncogenes within the nucleus of cancer cells.
-
Central role of β-catenin in anticancer effects of cardiac hormones.
Anticancer research, 2013Co-Authors: William Paul Skelton, Michelle Skelton, David L. VeselyAbstract:Background: β-Catenin causes malignant growth of colonic, pancreatic and renal cancer. Four cardiac hormones, namely atrial natriuretic peptide (ANP), Vessel Dilator, long-acting natriuretic peptide (LANP) and kaliuretic peptide eliminate up to 80% of human pancreatic carcinomas growing in mice. Materials and Methods: Four cardiac hormones were evaluated for their ability to reduce the expression of human β-catenin, measured by enzyme-linked immunosorbent assay (ELISA) in human colorectal, pancreatic and renal cancer cells. Results: Vessel Dilator, LANP, kaliuretic peptide, and ANP, over a concentration range of 100 pM to 10 μM, maximally reduced expression of β-catenin in human colorectal cancer cells by 78%, 71%, 69%, and 83%, respectively. Vessel Dilator, LANP, kaliuretic peptide, and ANP reduced β-catenin expression in human pancreatic cancer cells by 76%, 66%, 72%, and 88%, and by 64%, 54%, 58% and 73%, in human renal cancer cells, respectively. Conclusion: Part of the anticancer action of these four cardiac hormones is a potent inhibition of β-catenin. β-Catenin is a multifunctional protein, located on the intracellular side of the cytoplasmic membrane, that causes
Douglas D. Schocken - One of the best experts on this subject based on the ideXlab platform.
-
Combined treatment with Vessel Dilator and kaliuretic hormone in persons with congestive heart failure.
Experimental Biology and Medicine, 2004Co-Authors: Hamang Patel, John R. Dietz, Ashley Owen, Gloria I. San Miguel, Michael T. Mccormick, Douglas D. Schocken, David L. VeselyAbstract:Vessel Dilator and kaliuretic hormone, two cardiovascular peptide hormones, enhance urine flow 2- to 13-fold and 4-fold, respectively, in persons with class III New York Heart Association congestive heart failure (CHF). The natriuresis and diuresis secondary to Vessel Dilator and kaliuretic hormone are not blunted as are atrial natriuretic peptide and brain natriuretic peptide effects in persons with CHF compared with healthy individuals. The present investigation determined if the two peptide hormones that do not have blunted effects in persons with CHF may have added beneficial effects when given simultaneously to individuals with class III CHF. Together with each at 100 ng/kg of body weight per minute, Vessel Dilator and kaliuretic hormone increased urine flow rate 3.5-fold (P < 0.05) compared with their 60-min baseline and control CHF subjects' urine flow rates. Combined, they enhanced the excretion rate of sodium a maximum of 3.6-fold (P < 0.05) with 2.5- and 2-fold enhancement 2 and 3 hrs after infusion. These data indicate that Vessel Dilator and kaliuretic hormone have diuretic and natriuretic effects when used in combination, but these effects are not additive over their individual effects in persons with CHF.
-
Four cardiac hormones increase circulating concentrations of luteinizing hormone and testosterone
Endocrine, 2002Co-Authors: David L. Vesely, Gloria I. San Miguel, William R. Gower, Imran Hassan, Douglas D. SchockenAbstract:This study was designed to determine whether four peptide hormones consisting of amino acids 1–30—long-acting natriuretic hormone (LANH), 31–67 (Vessel Dilator), 79–98 (kaliuretic hormone), and 99–126 (atrial natriuretic hormone [ANH])—of the 126 amino acid atrial natriuretic prohormone increase the circulating concentration of testosterone in healthy humans ( n =30). Vessel Dilator, kaliuretic hormone, LANH, and ANH increased the circulating concentration of testosterone 3.8, 2.6, 3.9, and 3.4-fold, respectively ( p
-
Atrial natriuretic hormone, Vessel Dilator, long acting natriuretic hormone, and kaliuretic hormone decrease circulating prolactin concentrations.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2002Co-Authors: David L. Vesely, Gloria I. San Miguel, Imran Hassan, Douglas D. SchockenAbstract:The present investigation was designed to test whether four cardiac hormones--long acting natriuretic hormone, Vessel Dilator, kaliuretic hormone and atrial natriuretic hormone--decrease the circulating concentration of prolactin in humans (n = 30). Vessel Dilator, kaliuretic hormone, long acting natriuretic hormone and atrial natriuretic hormone decreased the circulating concentration of prolactin to 3 %, 31 %, 27 %, and 23 % of control values, respectively, at the end of their infusions when infused at concentrations of 100 ng/kg body weight per minute for 60 minutes (p < 0.001 for each). Vessel Dilator, kaliuretic hormone, long acting natriuretic hormone and atrial natriuretic hormone had sustained effects on modulating prolactin's concentrations, with circulating concentrations of 1 %, 64 %, 28 %, and 2 % of control values (p < 0.001) 3 hours after stopping their respective infusions. These results suggest that there are four circulating prolactin-inhibitory hormones in addition to the hypothalamic mediators, dopamine and corticotropin-releasing hormone, which modulate prolactin release. These peptide hormones' ability to decrease circulating prolactin concentrations may be mediated in part by dopamine and in part by their demonstrated ability to decrease corticotropin-releasing hormone concentrations, which stimulate prolactin release.
-
Intact negative feedback of four cardiac hormones in congestive heart failure
Metabolism: clinical and experimental, 2002Co-Authors: David L. Vesely, Gloria I. San Miguel, Imran Hassan, Douglas D. SchockenAbstract:In 30 individuals with class III congestive heart failure (CHF), negative feedback of 4 cardiac peptide hormones, ie, long-acting natriuretic peptide (LANP), Vessel Dilator, kaliuretic peptide, and atrial natriuretic factor (ANF) from the same 126-amino acid (aa) prohormone were studied with the infusion of 100 ng/kg body weight (BW) for 60 minutes of each of the 4 cardiac hormones and a saline control (n = 6 for each). LANP decreased the circulating concentrations of Vessel Dilator, kaliuretic peptide, and ANF by 24%, 55%, and 30%, respectively. Vessel Dilator decreased the circulating concentrations of ANF, kaliuretic peptide, and LANP 27%, 12%, and 62%, respectively. Kaliuretic peptide decreased the circulating concentrations of LANP, ANF, and Vessel Dilator 89%, 67%, and 70%, respectively. ANF decreased the circulating concentrations of LANP, Vessel Dilator, and kaliuretic peptide 88%, 59%, and 98%, respectively. Infusion of each of these 4 cardiac hormones decreased the excretion of the other 3 hormones into the urine by 11% to 92%. These results suggest that the respective cardiac hormones inhibit the release of each other rather than their breakdown, which would have increased their urinary concentrations. The feedback regulation of these hormones found previously in healthy humans is, thus, preserved in persons with CHF despite their increased endogenous circulating concentrations.
-
Atrial natriuretic hormone, Vessel Dilator, long-acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of total and free T4 and free T3 with reciprocal increase in TSH
The Journal of clinical endocrinology and metabolism, 2001Co-Authors: David L. Vesely, Gloria I. San Miguel, William R. Gower, Imran Hassan, Douglas D. SchockenAbstract:The present investigation was designed to determine whether atrial natriuretic peptides (ANPs) consisting of amino acids 1–30[ i.e. long-acting natriuretic hormone (LANH)], 31–67 (Vessel Dilator), 79–98 (kaliuretic hormone), and 99–126 (atrial natriuretic hormone [ANH]) of the 126-amino acid ANH prohormone decrease the circulating concentrations of total and free T4 and/or free T3 in healthy humans (n = 30). Vessel Dilator, kaliuretic hormone, LANH, and ANH decreased the circulating concentrations of total T4 by 61%, 58%, 47%, and 55% and of free T4 by 60%, 67%, 79%, and 79%, whereas free T3 decreased 72%, 67%, 71%, and 67% (P < 0.05 for each), respectively, when infused at 100 ng/kg BW·min for 60 min. Vessel Dilator, kaliuretic hormone, LANH, and ANH simultaneously increased circulating TSH concentrations 4- to 12.5-fold (P < 0.004). The decreases in T4 and T3 with reciprocal increases in TSH lasted 2–3 h after cessation of the respective ANP infusions. The reciprocal increase in TSH with the decreases i...
Meghan L. Lane - One of the best experts on this subject based on the ideXlab platform.
-
Subcutaneous pharmacokinetics of the cardiac hormone Vessel Dilator.
Clinical and experimental pharmacology & physiology, 2014Co-Authors: Qingyu Zhou, Glenn Whelan, Shu-feng Zhou, Meghan L. Lane, David L. VeselyAbstract:Summary Vessel Dilator, a hormone synthesized in the heart, eliminates 71% of human small-cell lung cancers and 67% of human breast cancers growing in mice when given subcutaneously (s.c.) via osmotic pumps. The pharmacokinetics of s.c. administered Vessel Dilator have not been evaluated previously. In the present study, the pharmacokinetics of Vessel Dilator following s.c. bolus (ScB) or 3 h s.c. infusion (ScI) were compared with those following i.v. bolus (IvB) administration in male Fischer 344 rats. The half-life (t½) of Vessel Dilator after ScI, IvB and ScB was 54, 43 and 30 min, respectively. The tmax for Vessel Dilator after IvB, ScB and ScI administration was 1.5, 23 and 156 min, respectively, whereas the corresponding Cmax values were 3749, 887 and 471 ng/L (normalized against the dose used for ScB and IvB). The area under the curve (AUC0–∞) for Vessel Dilator was 1166, 880 and 1652 ng h/mL (normalized) following IvB, ScB and ScI administration, respectively. The volume of distribution for Vessel Dilator was 2.38, 0.92 and 1.08 L following IvB, ScB and SCI administration, respectively; corresponding clearance values were 1.69, 1.50 and 0.78 L/h, respectively. Plasma concentrations of Vessel Dilator after each of the three methods of administration mirrored their predicted concentration–time profiles. We conclude that Vessel Dilator administered via ScI has a significantly greater AUC and t½ and slowed clearance compared with IvB or ScB administration (P
-
subcutaneous pharmacokinetics of the cardiac hormone Vessel Dilator
Clinical and Experimental Pharmacology and Physiology, 2014Co-Authors: Qingyu Zhou, Glenn Whelan, Shu-feng Zhou, Meghan L. Lane, David L. VeselyAbstract:Summary Vessel Dilator, a hormone synthesized in the heart, eliminates 71% of human small-cell lung cancers and 67% of human breast cancers growing in mice when given subcutaneously (s.c.) via osmotic pumps. The pharmacokinetics of s.c. administered Vessel Dilator have not been evaluated previously. In the present study, the pharmacokinetics of Vessel Dilator following s.c. bolus (ScB) or 3 h s.c. infusion (ScI) were compared with those following i.v. bolus (IvB) administration in male Fischer 344 rats. The half-life (t½) of Vessel Dilator after ScI, IvB and ScB was 54, 43 and 30 min, respectively. The tmax for Vessel Dilator after IvB, ScB and ScI administration was 1.5, 23 and 156 min, respectively, whereas the corresponding Cmax values were 3749, 887 and 471 ng/L (normalized against the dose used for ScB and IvB). The area under the curve (AUC0–∞) for Vessel Dilator was 1166, 880 and 1652 ng h/mL (normalized) following IvB, ScB and ScI administration, respectively. The volume of distribution for Vessel Dilator was 2.38, 0.92 and 1.08 L following IvB, ScB and SCI administration, respectively; corresponding clearance values were 1.69, 1.50 and 0.78 L/h, respectively. Plasma concentrations of Vessel Dilator after each of the three methods of administration mirrored their predicted concentration–time profiles. We conclude that Vessel Dilator administered via ScI has a significantly greater AUC and t½ and slowed clearance compared with IvB or ScB administration (P < 0.001), suggesting that s.c. infusion is the preferred method of administration, based on pharmacokinetics, to treat cancers.
-
Cardiac hormones target nuclear oncogenes c-Fos and c-Jun in carcinoma cells.
European journal of clinical investigation, 2013Co-Authors: Neil J. Manimala, Meghan L. Lane, Chelsea Frost, Mariana Higuera, Rana Beg, David L. VeselyAbstract:Background c-Fos is a cellular proto-oncogene which dimerizes with c-Jun proto-oncogene to form AP-1 transcription factor, which upregulates transcription of genes involved in proliferation and cancer formation. Four cardiac hormones, that is, long-acting natriuretic peptide (LANP), Vessel Dilator, kaliuretic peptide (KP) and atrial natriuretic peptide (ANP) with anticancer effects in vivo are potent inhibitors of the Ras-MEK 1/2-ERK 1/2 kinase cascade and signal transducer and activator of transcription-3 (STAT-3) that activate c-Fos and c-Jun. These four cardiac hormones were investigated for their effects on proto-oncogenes c-Fos and c-Jun within the nucleus of cancer cells. Materials and methods Four cardiac hormones were evaluated for their ability to decrease proto-oncogenes c-Fos and c-Jun, measured by ELISA in extracted nuclei of three human cancer cell lines. Results Vessel Dilator, LANP, KP and ANP over a concentration range of 100 pM–10 μM, maximally decreased c-Fos by 61%, 60%, 61% and 59% in human hepatocellular cancer cells, by 82%, 74%, 78% and 74% in small-cell lung cancer cells, and by 82%, 73%, 78% and 74% in human renal adenocarcinoma cells. c-Jun was maximally reduced by Vessel Dilator, LANP, KP and ANP by 43%, 31%, 61% and 35% in hepatocellular cancer cells, by 65%, 49%, 59% and 40% in small-cell lung cancer cells, and by 47%, 43%, 57% and 49% in renal cancer cells. Conclusion Four cardiac hormones are potent inhibitors of c-Fos and c-Jun proto-oncogenes within the nucleus of cancer cells.
-
Potent selective inhibition of STAT 3 versus STAT 1 by cardiac hormones
Molecular and Cellular Biochemistry, 2012Co-Authors: Meghan L. Lane, William P Skelton, Jennifer P. Nguyen, Michelle Skelton, Chelsea D. Frost, David L. VeselyAbstract:Signal transducers and activators of transcription (STATs) are the final “switches” that activate gene expression patterns that lead to human malignancy. Extracellular signal-regulated kinases (ERK 1/2) activate STAT 3; four cardiovascular hormones inhibit ERK 1/2 kinases, leading to the hypothesis that they may also inhibit STATs. These four cardiac hormones, i.e., Vessel Dilator, long-acting natriuretic peptide (LANP), kaliuretic peptide, and atrial natriuretic peptide (ANP), eliminate human cancers growing in mice. These four cardiac hormones’ effects on STATs 1 and 3 were examined in human small-cell lung cancer and human pancreatic adenocarcinoma cells. Vessel Dilator, LANP, kaliuretic peptide, and ANP maximally decreased STAT 3 by 88, 54, 55, and 65 %, respectively, at their 1 μM concentrations in human small-cell lung cancer cells and STAT 3 by 66, 57, 70, and 77 % in human pancreatic adenocarcinoma cells, respectively. The cardiac hormones (except LANP) also significantly decreased STAT 3 measured by Western blots. These cardiac hormones did not decrease STAT 1 in either human small-cell lung cancer or pancreatic adenocarcinoma cells. We conclude that these four cardiac hormones are significant inhibitors of STAT 3, but not STAT 1, in human small-cell lung cancer and pancreatic adenocarcinoma cells, which suggests a specificity for these hormones’ anticancer mechanism(s) of action enzymology in human cancer cells.
-
Novel dual inhibitors of vascular endothelial growth factor and VEGFR2 receptor.
European journal of clinical investigation, 2012Co-Authors: Jennifer P. Nguyen, Meghan L. Lane, William Paul Skelton, Chelsea Frost, Michelle Skelton, David L. VeselyAbstract:Background Vascular endothelial growth factor (VEGF) helps control tumour growth via causing new capillaries growth in tumours. Four cardiac hormones [i.e. Vessel Dilator, long-acting natriuretic peptide (LANP), kaliuretic peptide (KP) and atrial natriuretic peptide (ANP)] that eliminate up to up to 86% of human small-cell lung cancers growing in mice were investigated for their effects on VEGF and the VEGFR2 ⁄ KDR ⁄ Flk-1 receptor. The VEGFR2 receptor is the main receptor mediating VEGF’s cancer-enhancing effects. Materials and Methods Four cardiac hormones were evaluated for their ability to decrease VEGF ⁄ VEGFR2 measured by ELISAs in three human cancer cell lines. Results Vessel Dilator, LANP, KP and ANP, over a concentration range of 100 pM to 10 lM, maximally decreased the VEGFR2 receptor in human pancreatic adenocarcinoma cells by 48%, 49%, 74% and 83%. Vessel Dilator, LANP, KP and ANP decreased the VEGFR2 receptor by 77%, 89%, 88% and 67% in human small-cell lung cancer cells and by 48%, 92%, 64% and 71% in human prostate cancer cells. These results were confirmed with the cardiac hormones also decreasing the VEGFR2 receptor measured by Western blots. VEGF itself in pancreatic carcinoma cells was decreased by 42%, 58%, 36% and 40% by Vessel Dilator, LANP, KP and ANP. VEGF levels were decreased 25%, 23%, 17% and 23% in small-cell lung cancer cells and decreased by 24%, 20%, 23% and 24% in prostate cancer cells by Vessel Dilator, LANP, KP and ANP. Conclusion Four cardiac hormones are the first dual inhibitors of VEGF and the VEGFR2 ⁄ KDR ⁄ Flk-1 receptor.
Michael T. Mccormick - One of the best experts on this subject based on the ideXlab platform.
-
Combined treatment with Vessel Dilator and kaliuretic hormone in persons with congestive heart failure.
Experimental Biology and Medicine, 2004Co-Authors: Hamang Patel, John R. Dietz, Ashley Owen, Gloria I. San Miguel, Michael T. Mccormick, Douglas D. Schocken, David L. VeselyAbstract:Vessel Dilator and kaliuretic hormone, two cardiovascular peptide hormones, enhance urine flow 2- to 13-fold and 4-fold, respectively, in persons with class III New York Heart Association congestive heart failure (CHF). The natriuresis and diuresis secondary to Vessel Dilator and kaliuretic hormone are not blunted as are atrial natriuretic peptide and brain natriuretic peptide effects in persons with CHF compared with healthy individuals. The present investigation determined if the two peptide hormones that do not have blunted effects in persons with CHF may have added beneficial effects when given simultaneously to individuals with class III CHF. Together with each at 100 ng/kg of body weight per minute, Vessel Dilator and kaliuretic hormone increased urine flow rate 3.5-fold (P < 0.05) compared with their 60-min baseline and control CHF subjects' urine flow rates. Combined, they enhanced the excretion rate of sodium a maximum of 3.6-fold (P < 0.05) with 2.5- and 2-fold enhancement 2 and 3 hrs after infusion. These data indicate that Vessel Dilator and kaliuretic hormone have diuretic and natriuretic effects when used in combination, but these effects are not additive over their individual effects in persons with CHF.
-
Comparison of Vessel Dilator and long-acting natriuretic peptide in the treatment of congestive heart failure.
American Heart Journal, 1999Co-Authors: David L. Vesely, John R. Dietz, Michael T. Mccormick, James R. Parks, Ernest A. Antwi, Rose M. Overton, Guillermo Cintron, Douglas D. SchockenAbstract:Background Long-acting natriuretic peptide (LANP; proANF 1-30) and Vessel Dilator (proANF 31-67) enhance sodium and water excretion in healthy human beings. The current investigation was designed to compare the beneficial effects of LANP and Vessel Dilator in persons with congestive heart failure (CHF). Methods and Results LANP and Vessel Dilator (100 ng/kg body weight/min, respectively) were given intravenously for 60 minutes to subjects with New York Heart Association class III CHF (n = 17) while their urine volume and sodium and potassium excretion were monitored. Vessel Dilator increased urine flow more than 5-fold, which was still increased (P < .001) 3 hours after stopping its infusion. Vessel Dilator enhanced sodium excretion 3-fold in subjects with CHF (P < .01), which was still significantly (P < .01) elevated 3 hours after infusion. The effects of LANP were diminished, with urine flow only increasing 2-fold (P < .05). The fractional excretion of sodium increased maximally 6-fold secondary to Vessel Dilator and 3-fold with LANP. The CHF control patients had no changes in the above parameters. Part of the diminished response to LANP was found to be caused by its rapid decrease in the circulation of individuals with CHF. Conclusions These results indicate that Vessel Dilator has significant beneficial diuretic and natriuretic properties, which are not diminished, whereas the effects of LANP are diminished in human beings with CHF compared with healthy individuals. (Am Heart J 1999;138:625-32.)
-
Comparison of Vessel Dilator and long-acting natriuretic peptide in the treatment of congestive heart failure.
American heart journal, 1999Co-Authors: D L Vesely, John R. Dietz, Michael T. Mccormick, James R. Parks, Ernest A. Antwi, Rose M. Overton, Guillermo Cintron, Douglas D. SchockenAbstract:Long-acting natriuretic peptide (LANP; proANF 1-30) and Vessel Dilator (proANF 31-67) enhance sodium and water excretion in healthy human beings. The current investigation was designed to compare the beneficial effects of LANP and Vessel Dilator in persons with congestive heart failure (CHF). LANP and Vessel Dilator (100 ng/kg body weight/min, respectively) were given intravenously for 60 minutes to subjects with New York Heart Association class III CHF (n = 17) while their urine volume and sodium and potassium excretion were monitored. Vessel Dilator increased urine flow more than 5-fold, which was still increased (P <.001) 3 hours after stopping its infusion. Vessel Dilator enhanced sodium excretion 3-fold in subjects with CHF (P <.01), which was still significantly (P <.01) elevated 3 hours after infusion. The effects of LANP were diminished, with urine flow only increasing 2-fold (P <.05). The fractional excretion of sodium increased maximally 6-fold secondary to Vessel Dilator and 3-fold with LANP. The CHF control patients had no changes in the above parameters. Part of the diminished response to LANP was found to be caused by its rapid decrease in the circulation of individuals with CHF. These results indicate that Vessel Dilator has significant beneficial diuretic and natriuretic properties, which are not diminished, whereas the effects of LANP are diminished in human beings with CHF compared with healthy individuals.
-
Vessel Dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure
Circulation, 1998Co-Authors: David L. Vesely, John R. Dietz, Michael T. Mccormick, James R. Parks, Guillermo Cintron, Mohammad Baig, Douglas D. SchockenAbstract:Background—Vessel Dilator, a 37–amino acid peptide hormone synthesized in the heart, enhances urine flow 4- to 12-fold and sodium excretion 3- to 6-fold in healthy humans. The present investigation was designed to determine whether Vessel Dilator might have similar beneficial effects in persons with congestive heart failure (CHF). Methods and Results—Vessel Dilator (100 ng/kg body weight per minute) given intravenously for 60 minutes to NYHA class III CHF subjects increased urine flow 2- to 13-fold, which was still increased (P<0.001) 3 hours after its infusion was stopped. Vessel Dilator enhanced sodium excretion 3- to 4-fold in CHF subjects (P<0.01), which was still significantly (P<0.01) elevated 3 hours after infusion. Vessel Dilator decreased systemic vascular resistance 24%, pulmonary vascular resistance 25%, pulmonary capillary wedge pressure 33%, and central venous pressure 27% while increasing cardiac output 34%, cardiac index 35%, and stroke volume index 24% without significantly affecting heart...
-
Vessel Dilator Enhances Sodium and Water Excretion and Has Beneficial Hemodynamic Effects in Persons With Congestive Heart Failure
Circulation, 1998Co-Authors: David L. Vesely, John R. Dietz, Michael T. Mccormick, James R. Parks, Guillermo Cintron, Mohammad Baig, Douglas D. SchockenAbstract:Background—Vessel Dilator, a 37–amino acid peptide hormone synthesized in the heart, enhances urine flow 4- to 12-fold and sodium excretion 3- to 6-fold in healthy humans. The present investigation was designed to determine whether Vessel Dilator might have similar beneficial effects in persons with congestive heart failure (CHF). Methods and Results—Vessel Dilator (100 ng/kg body weight per minute) given intravenously for 60 minutes to NYHA class III CHF subjects increased urine flow 2- to 13-fold, which was still increased (P
Arthur M. Boudreaux - One of the best experts on this subject based on the ideXlab platform.
-
Preemptive Vessel Dilator cricothyrotomy aids in the management of upper airway obstruction
Canadian Journal of Anesthesia, 2005Co-Authors: James R. Boyce, Glenn E. Peters, William R. Carroll, J. Scott Magnuson, Allison Mccrory, Arthur M. BoudreauxAbstract:Objectif Démontrer que la crico-thyrotomie préventive avec un dilatateur vasculaire peut aider la prise en charge ďune obstruction des voies respiratoires. Méthode Le comité ďexamen a approuvé notre étude rétrospective auprès de 88 patients soumis à cette technique. Les anesthésiologistes et les chirurgiens, auteurs du présent article, ont été directement appelés à participer. Toutes les crico-thyrotomies avec dilatateur vasculaire ont été réalisées dans les salles ďopération du University Hospital, UAB, Medical Center. Les patients choisis présentaient une lésion oropharyngée, habituellement un épithéliome malpighien, qui obstruait les voies respiratoires de façon tellement étendue qu’une obstruction complète des voies aériennes était à craindre pendant ľinduction de ľanesthésie. Avant ľinduction, le dilatateur vasculaire a été inséré dans la lumière de la trachée par la membrane cricotyroïdienne. ľoxygénation a été maintenue avec la ventilation en jet par un appareil à jet Sanders. ľâge, le poids, la saturation initiale en O_2 et la plus faible saturation, la première ETCO_2 enregistrée, la tension artérielle et la durée de la ventilation en jet ont été notés. Résultats Les voies aériennes ont été bien protégées chez tous les patients. Il n’y a pas eu de décès ni de séquelles hypoxiques postopératoires, seulement des complications mineures. Conclusion La crico-thyrotomie avec dilatateur vasculaire, utilisée comme technique préventive chez des patients qui présentent une obstruction oropharyngée, peut s’ajouter avantageusement aux appareils de prise en charge des voies aériennes par les anesthésiologistes. Purpose Our objective was to demonstrate that preemptive Vessel Dilator cricothyrotomy may be useful when managing the patient with airway obstruction. Methods An Institutional Review Board approved retrospective study was undertaken in 88 patients for whom this technique was selected. The anesthesiologists and surgeons identified as authors were directly involved in the care of these patients. All Vessel Dilator cricothyrotomies were performed in the operating rooms of University Hospital, UAB, Medical Center. The patients selected for this airway management technique were afflicted with some type of supraglottic lesion, usually squamous cell carcinoma, which was obstructing their airways to an extent that complete airway obstruction during induction of anesthesia was a significant possibility. Prior to induction of anesthesia, the Vessel Dilator was inserted into the tracheal lumen through the cricothyroid membrane as described. Oxygenation was maintained with jet ventilation from a Sanders jetting device. Age, sex, weight, initial and lowest O_2 saturation, first recorded ETCO_2, blood pressure and duration of jet ventilation were recorded. Results The airways were successfully managed in all 88 patients with this technique. There were no deaths, and no postoperative hypoxic sequelae; also complications were minor. Conclusion Vessel Dilator cricothyrotomy as a preemptive procedure in the management of patients with significant supraglottic airway obstruction may be a useful addition to the anesthesiologists’ armamentarium of airway management devices.
-
Preemptive Vessel Dilator cricothyrotomy aids in the management of upper airway obstruction.
Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2005Co-Authors: James R. Boyce, Glenn E. Peters, William R. Carroll, J. Scott Magnuson, Allison Mccrory, Arthur M. BoudreauxAbstract:Purpose Our objective was to demonstrate that preemptive Vessel Dilator cricothyrotomy may be useful when managing the patient with airway obstruction.